Dutch Bioplastics Pioneer Avantium Raises 55 Million Euros to Launch Commercial Operations
Delfzijl, Sunday, 15 November 2026.
Avantium secured €55.45 million through a rights offering, resolving critical working capital shortfalls to fund the commercial launch of its flagship plant-based plastics facility by late 2026.
Capital Injection Stabilizes Liquidity Profile
Amsterdam-headquartered renewable chemistry company Avantium N.V. [2][7] finalized a critical €55.45 million capital increase on 11 November 2026 [4][6], issuing 33.6 million new ordinary shares priced at €1.65 per share [1][5]. Existing shareholders exercised their pre-emptive rights to absorb 85.7% of the offering, while the remaining 4.79 million rump shares saw high demand that exceeded available market supply [1][5]. Backing came from impact investor Invest-NL, which contributed €6.06 million, alongside €5 million from Pieter Kooi Holding and institutional underwriting provided by ABN Amro, BNP Paribas, and Stifel [1]. The issue price of €1.65 represented a steep discount compared to the theoretical ex-rights price of €2.6143 and the company’s pre-announcement closing price of €3.90 recorded on 27 October 2026 [1].
Bridging Balance Sheet Deficits and Start-Up Delays
The cash injection arrives at a pivotal operational juncture for the Dutch developer [1]. Avantium’s liquid reserves had dropped to €23.9 million by the end of June 2026 from €57.5 million at year-end 2025, reflecting a cash erosion of 33.6 million euros across the opening six months of the year [1]. Compounding this balance sheet pressure, the firm incurred an EBITDA loss of €18.8 million in the first half of 2026 on top of revenues sliding to €4.7 million [1]. Technical difficulties during the commissioning phase of the commercial facility in Delfzijl, Netherlands—specifically requiring repair programs for defective titanium welds that concluded in spring 2026—incurred an additional €7 million in capital expenditures [1][5]. By late October 2026, Avantium faced an impending €33 million working capital deficit over a 12-month horizon [1][5], a liquidity shortfall that company management expects the €55.45 million rights offering will successfully close for at least the next year [5].
Scaling Commercial Output in Delfzijl
Proceeds from the rights issue are deployed directly toward commissioning the Delfzijl Flagship Plant, recognized as the world’s first commercial-scale manufacturing plant for furandicarboxylic acid (FDCA) [1][2][4]. Operating proprietary YXY Technology tested at a pilot scale in Geleen [2], Avantium catalytically transforms plant-based sugars into FDCA building blocks to produce polyethylene furanoate (PEF) [2][5], marketed under the registered circular polymer brand releaf® [2][7]. Although original operational roadmaps targeted completion of the ramp-up around mid-2026 [5], the facility has already produced initial volumes of FDCA and is currently qualifying commercial materials for end clients [3][5]. Chief Executive Tom van Aken aims to achieve first official commercial deliveries by the end of December 2026 [1][4][5].
Securing Institutional Loans and Commercial Demand
To sustain its long-term industrial ramp-up, Avantium negotiated a framework agreement with the Northern Netherlands Development Agency (NOM) for a €20 million loan facility [1][5]. The prospective credit line is structured into four sequential tranches of €5 million tied to industrial milestones, including establishing a corporate head office in Groningen [1]. Supported by Dutch Minister of Economic Affairs and Climate Heleen Herbert via Parliamentary funding mechanisms [5], the earliest disbursement of the initial €5 million tranche is slated for 1 March 2027, subject to definitive approvals from national authorities and the Province of Groningen [1]. In parallel, commercial momentum expanded on 12 November 2026, when Avantium entered a capacity reservation contract with chemical distributor Will & Co [2][4][6]. The agreement secures future FDCA supply for coatings, adhesives, sealants, and elastomers (CASE) applications from future licensed manufacturing plants [2][4][6], reinforcing Avantium’s global YXY licensing framework by validating clear commercial uptake across traditional industrial polymers [2][4].
Bronnen
- ioplus.nl
- newsroom.avantium.com
- www.linkedin.com
- www.polyestertime.com
- www.industrielinqs.nl
- www.ideal-investisseur.fr
- www.nombase.com
- www.threads.com